ClinConnect ClinConnect Logo
Search / Trial NCT05952583

Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation

Launched by LEIDEN UNIVERSITY MEDICAL CENTER · Jul 11, 2023

Trial Information

Current as of July 01, 2025

Recruiting

Keywords

S Fgr S Iugr Selective Fetal Growth Restriction

ClinConnect Summary

This clinical trial is studying a condition called selective fetal growth restriction (sFGR) in pregnancies with monochorionic diamniotic twins, meaning the twins share a placenta but have separate amniotic sacs. The goal is to better understand how this condition affects the babies and to improve the way doctors can predict outcomes for these pregnancies. Currently, there isn't a specific treatment for sFGR, so it’s really important to be able to predict if and when the babies might be at risk, which will help parents and doctors make informed decisions about care and monitoring.

To participate in this study, you must have a twin pregnancy where one baby is diagnosed with sFGR before the 28th week of pregnancy. Both parents need to be at least 18 years old and able to give consent for themselves and their babies. Participants can expect to be followed closely until the babies are two years old after birth, which will help researchers gather valuable information about the health and development of the children. This study is unique because it’s the first of its kind to look into these important questions on an international level, and it aims to provide clearer insights and support for families facing this challenging situation.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • MCDA twin pregnancy
  • Diagnosis of sFGR before 28+0 weeks of GA (independent of Doppler flows)
  • Pregnant woman ≥ 18 years and able to consent
  • Partner (who has (future) parental responsibility - if applicable) ≥ 18 years and able to consent
  • Written informed consent of both parents (if applicable) for participation in the longitudinal follow-up until 2 years after birth)
  • Exclusion Criteria:
  • The presence of lethal anomalies (one or both fetuses)
  • Multiple pregnancy higher order than twins;
  • TTTS/TAPS present at moment of sFGR diagnosis.

About Leiden University Medical Center

Leiden University Medical Center (LUMC) is a prominent academic medical center located in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and high-quality patient care. As a clinical trial sponsor, LUMC focuses on translating scientific discoveries into effective therapies, fostering collaborations between researchers, clinicians, and industry partners. The center is dedicated to conducting rigorous clinical studies across various medical fields, ensuring adherence to ethical standards and regulatory requirements while prioritizing patient safety and outcomes. Through its multidisciplinary approach, LUMC aims to contribute significantly to the understanding and treatment of complex health conditions, driving progress in personalized medicine and improving global health.

Locations

Boston, Massachusetts, United States

Leuven, , Belgium

Toronto, Ontario, Canada

Leiden, Zuid Holland, Netherlands

Barcelona, , Spain

Stockholm, , Sweden

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported